{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"AML: proportion of patients with a molecular complete response (CR); MM: proportion of patients with a molecular CR.","groups":[{"description":"Patients were scheduled to receive a single intravenous (iv) infusion of CD44v6.CAR-transduced autologous lymphocytes at day 0, after lymphodepleting chemotherapy with cyclophosphamide iv (500 mg/m2) and fludarabine iv (30 mg/m2) performed daily from day -5 to day -3\n\nThe dose of iv infused MLM-CAR44.1 T-cells is:\n\nPHASE I: 0.5x10E6/Kg or 1x10E6/Kg or 2x10E6/Kg according to the BOIN design. PHASE IIa: a dose of MLM-CAR44.1 T-cells corresponding to the maximum tolerated dose (MTD)","id":"OG000","title":"MLM-CAR44.1 T-cells Infusion"}],"populationDescription":"Data were not collected because Phase IIa was not performed due to early end of trial","reportingStatus":"POSTED","timeFrame":"AML: 2 months after infusion, assessed as day 0. MM: 3 months after infusion, assessed as day 0","title":"Exploratory Outcome of Phase IIa: Percentages of Patients With Minimal Residual Disease","type":"OTHER_PRE_SPECIFIED"}